Carl Zeiss Meditec (AFX) Stock Forecast & Price Target

Compare

118 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AFX Analyst Ratings

Hold

3 Buy

5 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Carl

Zeiss Meditec

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AFX Stock 12 Month Forecast

Average Price Target

€47.46

▲(18.41% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Carl Zeiss Meditec in the last 3 months. The average price target is €47.46 with a high forecast of €54.00 and a low forecast of €35.10. The average price target represents a 18.41% change from the last price of €40.08.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"34":"€34","61":"€61","40.75":"€40.8","47.5":"€47.5","54.25":"€54.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47.46,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€47.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€35.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[34,40.75,47.5,54.25,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.32,44.14153846153846,44.963076923076926,45.784615384615385,46.606153846153845,47.42769230769231,48.24923076923077,49.07076923076923,49.892307692307696,50.713846153846156,51.535384615384615,52.35692307692308,53.17846153846154,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.32,43.63846153846154,43.956923076923076,44.27538461538462,44.59384615384615,44.91230769230769,45.23076923076923,45.54923076923077,45.86769230769231,46.18615384615385,46.504615384615384,46.823076923076925,47.14153846153846,{"y":47.46,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.32,42.68769230769231,42.05538461538462,41.42307692307693,40.79076923076923,40.15846153846154,39.526153846153846,38.893846153846155,38.261538461538464,37.62923076923077,36.99692307692308,36.364615384615384,35.73230769230769,{"y":35.1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":56.429,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.103,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58.51,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":59.501,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.85,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.32,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€54.00

Average Price Target€47.46

Lowest Price Target€35.10

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Felton

Goldman Sachs

€60→€54

Buy

34.73%

Upside

Reiterated

12/17/25

Goldman Sachs Reaffirms Their Buy Rating on Carl Zeiss Meditec (0DHC)

Susannah Ludwig

Bernstein

€54.6→€50.55

Buy

26.12%

Upside

Reiterated

12/16/25

Bernstein Keeps Their Buy Rating on Carl Zeiss Meditec (0DHC)

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Hold

―

Reiterated

12/16/25

Falko Friedrichs

Deutsche Bank

€46→€44

Hold

9.78%

Upside

Reiterated

12/15/25

Deutsche Bank Remains a Hold on Carl Zeiss Meditec (0DHC)

David Adlington

J.P. Morgan

€35.1

Sell

-12.43%

Downside

Reiterated

12/15/25

Carl Zeiss Meditec (0DHC) Receives a Sell from J.P. Morgan

Jack Reynolds-Clark

RBC Capital

€47

Hold

17.27%

Upside

Reiterated

12/11/25

RBC Capital Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)

Jonathon Unwin

Barclays

€52→€49

Buy

22.26%

Upside

Reiterated

12/11/25

Barclays Remains a Buy on Carl Zeiss Meditec (0DHC)

Graham Doyle

UBS

€53

Hold

32.24%

Upside

Reiterated

12/10/25

Carl Zeiss Meditec (0DHC) Gets a Hold from UBS

Sam England

Berenberg Bank

€47

Hold

17.27%

Upside

Reiterated

09/26/25

Carl Zeiss Meditec (0DHC) Gets a Hold from Berenberg Bank

Oliver Reinberg

Kepler Capital

€46

Hold

14.77%

Upside

Reiterated

09/11/25

Kepler Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Alexander Galitsa

Hauck & Aufhaeuser

€70→€68

Buy

69.66%

Upside

Reiterated

08/08/25

Carl Zeiss Meditec (0DHC) Receives a Buy from Hauck & Aufhaeuser

Dylan Van Haaften

Stifel Nicolaus

€60→€50

Hold

24.75%

Upside

Reiterated

08/05/25

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

―

Hold

―

Reiterated

05/28/25

DZ BANK AG Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Felton

Goldman Sachs

€60→€54

Buy

34.73%

Upside

Reiterated

12/17/25

Goldman Sachs Reaffirms Their Buy Rating on Carl Zeiss Meditec (0DHC)

Susannah Ludwig

Bernstein

€54.6→€50.55

Buy

26.12%

Upside

Reiterated

12/16/25

Bernstein Keeps Their Buy Rating on Carl Zeiss Meditec (0DHC)

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

Hold

―

Reiterated

12/16/25

Falko Friedrichs

Deutsche Bank

€46→€44

Hold

9.78%

Upside

Reiterated

12/15/25

Deutsche Bank Remains a Hold on Carl Zeiss Meditec (0DHC)

David Adlington

J.P. Morgan

€35.1

Sell

-12.43%

Downside

Reiterated

12/15/25

Carl Zeiss Meditec (0DHC) Receives a Sell from J.P. Morgan

Jack Reynolds-Clark

RBC Capital

€47

Hold

17.27%

Upside

Reiterated

12/11/25

RBC Capital Sticks to Its Hold Rating for Carl Zeiss Meditec (0DHC)

Jonathon Unwin

Barclays

€52→€49

Buy

22.26%

Upside

Reiterated

12/11/25

Barclays Remains a Buy on Carl Zeiss Meditec (0DHC)

Graham Doyle

UBS

€53

Hold

32.24%

Upside

Reiterated

12/10/25

Carl Zeiss Meditec (0DHC) Gets a Hold from UBS

Sam England

Berenberg Bank

€47

Hold

17.27%

Upside

Reiterated

09/26/25

Carl Zeiss Meditec (0DHC) Gets a Hold from Berenberg Bank

Oliver Reinberg

Kepler Capital

€46

Hold

14.77%

Upside

Reiterated

09/11/25

Kepler Capital Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Alexander Galitsa

Hauck & Aufhaeuser

€70→€68

Buy

69.66%

Upside

Reiterated

08/08/25

Carl Zeiss Meditec (0DHC) Receives a Buy from Hauck & Aufhaeuser

Dylan Van Haaften

Stifel Nicolaus

€60→€50

Hold

24.75%

Upside

Reiterated

08/05/25

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

―

Hold

―

Reiterated

05/28/25

DZ BANK AG Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Carl Zeiss Meditec

1 Month

xxx

Success Rate

18/34 ratings generated profit

Average Return

+1.69%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.94% of your transactions generating a profit, with an average return of +1.69% per trade.

3 Months

xxx

Success Rate

15/34 ratings generated profit

Average Return

-2.13%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.12% of your transactions generating a profit, with an average return of -2.13% per trade.

1 Year

Alexander GalitsaHauck & Aufhaeuser

Success Rate

5/34 ratings generated profit

Average Return

-19.57%

reiterated a buy rating 4 months ago

Copying Alexander Galitsa's trades and holding each position for 1 Year would result in 14.71% of your transactions generating a profit, with an average return of -19.57% per trade.

2 Years

xxx

Success Rate

4/34 ratings generated profit

Average Return

-33.44%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 11.76% of your transactions generating a profit, with an average return of -33.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AFX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AFX has received 8 Buy Ratings, 12 Hold Ratings, and 4 Sell Ratings. AFX average Analyst price target in the past 3 months is 47.46.

Each month's total comprises the sum of three months' worth of ratings.

AFX Financial Forecast

AFX Earnings Forecast

Next quarter’s earnings estimate for AFX is €0.37 with a range of €0.33 to €0.41. The previous quarter’s EPS was €0.59. AFX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year AFX has Performed in-line its overall industry.

AFX Sales Forecast

Next quarter’s sales forecast for AFX is €487.73M with a range of €467.95M to €507.50M. The previous quarter’s sales results were €1.18B. AFX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year AFX has Performed in-line its overall industry.

AFX Stock Forecast FAQ

What is DE:AFX’s average 12-month price target, according to analysts?

Based on analyst ratings, Carl Zeiss Meditec’s 12-month average price target is 47.46.

What is DE:AFX’s upside potential, based on the analysts’ average price target?

Carl Zeiss Meditec has 18.41% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Carl Zeiss Meditec a Buy, Sell or Hold?

Carl Zeiss Meditec has a consensus rating of Hold, which is based on 3 buy ratings, 5 hold ratings and 1 sell ratings.

What is Carl Zeiss Meditec’s share price target?

The average share price target for Carl Zeiss Meditec is 47.46. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €54.00 ,and the lowest forecast is €35.10. The average share price target represents 18.41% Increase from the current price of €40.08.

What do analysts say about Carl Zeiss Meditec?

Carl Zeiss Meditec’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Carl Zeiss Meditec?

To buy shares of DE:AFX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Carl Zeiss Meditec (AFX) Stock Forecast & Price Target

AFX Analyst Ratings

AFX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Carl Zeiss Meditec

AFX Analyst Recommendation Trends

AFX Financial Forecast

AFX Earnings Forecast

AFX Sales Forecast

AFX Stock Forecast FAQ

Detailed List of Analyst Forecasts